Recombinant new coronavirus vaccine (CHO cell) group

BIOLOGICAL5 trials

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Conditions

CoronavirusCoronavirus Disease 2019Prevention of COVID-19Safety and Efficacy

Phase 1

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

CompletedNCT04961359

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2021-07-03End: 2023-04-06Updated: 2023-04-25

Phase 3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Prevention of COVID-19, Safety and Efficacy

Start: 2020-12-16End: 2022-12-31Updated: 2022-01-19

Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus Disease 2019

Start: 2021-09-09End: 2022-12-31Target: 1680Updated: 2021-10-25

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

CompletedNCT05107375

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus Disease 2019

Start: 2021-09-03End: 2022-03-04Updated: 2023-06-08

Unknown Phase

Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

CompletedNCT05089045

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus Disease 2019

Start: 2021-08-31End: 2021-09-30Updated: 2021-10-22

Related Papers

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.

2023-02-1715 citations

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

New England Journal of Medicine2022-05-04248 citations

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

2021-03-24353 citations